Fresenius Brings In Transparency Change For Kabi Unit
Business On Track To Meet Or Exceed Its Targets For The Current Financial Year
Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.
You may also be interested in...
Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. In addition to the big news from Acutus, Apple, and Illumina, Masimo scored an important FDA clearance, Beta Bionics announced the US launch of its iLet bionic pancreas for Dexcom’s G7 CGM, and more.
Fresenius Kabi’s management spoke about the company’s revamped reporting segments for the second quarter, alongside its latest endeavors in biosimilars.
During a lengthy and comprehensive capital markets day, Fresenius Kabi spelled out its vision and plans for a return from the company’s burgeoning Biopharmaceuticals business, following years of major investment.